Guolian Securities gave Yuyue Healthcare and Sannuo Biotech ...

Guolian Securities gave Yuyue Healthcare and Sannuo Biotech a “buy” rating, and it is anticipated that they will bring continued performance growth to the market. At the same time, these companies need to be wary of increased market competition, product price reductions, insufficient marketing, and anticipated risks of new product development and overseas expansion.